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ABSTRACT
Background: We previously showed that growth hormone-releasing hormone 
(GHRH) agonists are cardioprotective following myocardial infarction (MI). Here, 
our aim was to evaluate the in vitro and in vivo activities of highly potent new GHRH 
agonists, and elucidate their mechanisms of action in promoting cardiac repair.
Methods and Results: H9c2 cells were cultured in serum-free medium, mimicking 
nutritional deprivation. GHRH agonists decreased calcium influx and significantly 
improved cell survival. Rats with cardiac infarction were treated with GHRH agonists or 
placebo for four weeks. MI size was reduced by selected GHRH agonists (JI-38, MR-356,  
MR-409); this accompanied an increased number of cardiac c-kit+ cells, cellular 
mitotic divisions, and vascular density. One week post-MI, MR-409 significantly 
reduced plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo. Gene 
expression studies revealed favorable outcomes of MR-409 treatment partially result 
from inhibitory activity on pro-apoptotic molecules and pro-fibrotic systems, and by 
elevation of bone morphogenetic proteins.
Conclusions: Treatment with GHRH agonists appears to reduce the inflammatory 
responses post-MI and may consequently improve mechanisms of healing and cardiac 
remod eling by regulating pathways involved in fibrosis, apoptosis and cardiac repair. 
Patients with cardiac dysfunction could benefit from treatment with novel GHRH agonists.
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INTRODUCTION
Current management of congestive heart failure (HF) 
serves to maximize the effectiveness of the remaining heart 
tissue in order to maintain an adequate cardiac output. 
However, even with the most advanced medical therapies 
for HF, morbidity and mortality remain high. Moreover, the 
susceptibility of the heart to injury and disease progression 
are markedly increased in advanced age. Consistent with 
the report from the American Heart Association Statistics 
Committee and Stroke Statistics Subcommittee, the 
incidence of HF per year rises to ~10 per 1000 population 
after 65 years of age [1]. Therefore, novel and innovative 
therapeutic approaches are urgently needed.
Besides the well-known renin-angiotensin-
aldosterone system, other mechanisms play an important 
role in the pathophysiology of HF, including those 
based on vasopressin, natriuretic peptides, endothelin, 
and TNF-α [2]. Secretory events which occur in 
cardiomyocytes and fibroblasts play a critical role in the 
progression of myocardial remodeling leading to heart 
failure [3]. Both of these cell types secrete a variety of 
growth factors, cytokines, and hormones that influence 
cardiomyocyte growth and fibroblast activation in 
paracrine and autocrine manners. Our group reported 
recently that receptors for growth hormone-releasing 
hormone (GHRH-R) are present on the cell membranes 
of both cardiomyocytes [4, 5] and fibroblasts [6], and 
mediate the direct effects of this hormone. GHRH itself 
functions as an autocrine/paracrine growth factor in benign 
conditions [7–15] and various malignancies [16–22]. 
In addition, agonists of GHRH improve the survival 
and growth of many cell types such as pancreatic β cells 
[31] and cardiac stem cells (CSCs) [23]. GHRH has also 
been shown to stimulate proliferation and migration of 
mouse embryonic fibroblasts in vitro and to accelerate 
wound healing in vivo [6].
Recently, Granata et al. found that GHRH promotes 
cardiomyocyte survival and protects against ischemia/
reperfusion injury in the isolated rat heart [24]. Our 
group has reported that after an experimental MI in rats, 
treatment with the GHRH agonist, JI-38, significantly 
decreased the degree of subsequent cardiac remodeling 
and dysfunction, suggesting a regenerative process [4, 5]. 
Most recently, boosting the cardiac reparative capacity 
by improving the intrinsic healing process has been 
increasingly considered as a novel therapeutic approach 
to complement repair deficiencies [25–27]. Accordingly, 
our group synthesized and investigated for their biological 
activity and cardioprotective effects additional new and 
more potent GHRH analogs. By incorporating non-natural 
amino acid substitutions into these synthetic analogs, we 
have increased their resistance to degradation, and their 
physiologic half-life. Thus the new GHRH agonists have 
significantly improved endocrine activity and stability 
making these agonists even more suitable for use in clinical 
settings [28]. The aim of the current study was to evaluate 
the in vitro and in vivo activities of these highly potent new 
GHRH analogs, and elucidate their mechanisms of action 
in promoting and/or enhancing cardiac repair.
RESULTS
Presence of GHRH ligand and GHRH receptor 
in H9c2 rat cardiomyoblast cell line
Reverse-transcribed mRNA from H9c2 cells and 
rat pituitary was subjected to RT-PCR. The amplicons for 
GHRH (195 bp), GHRH-R (110 bp), and β-actin (133 bp) 
were detected at their expected sizes (Figure 1).
Effect of GHRH agonists on H9c2 cell survival 
in a nutritionally deprived environment
H9c2 cells were cultured in a nutritionally deprived 
environment for 72 hours, their media containing various 
GHRH-agonists at 100 nmol/L concentration. Cells in 
a serum free medium without any hormonal additions 
served as controls. All the tested GHRH-agonists, except 
JI-38 and MR-502, significantly improved the viability of 
the cardiac cells after 72 hours of starvation, compared 
to their control. The survival of H9c2 cells was increased 
from 67.8% to 87.3% after the treatment with MR-361, 
from 67.8% to 85.8% with MR-367, from 74.5% to 87.6% 
with MR-403, and from 74.5% to 85.7% with MR-409 
(Figure 2A).
Figure 1: Expression of GHRH-R and GHRH mRNA in H9c2 cardiomyoblast cell line. The PCR products of GHRH-R, 
GHRH and β-actin were detected at their expected sizes: at 110 bp, 195 bp and 133 bp, respectively. Abbreviations: Pit: rat pituitary,  
Car: H9c2 cells, NEC: no enzyme (reverse transcriptase) control, M: marker.
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Effect of GHRH agonists on calcium 
mobilization in a nutritionally deprived 
environment
Calcium influx is associated with cell death, 
and increase in intracellular calcium indicates ensuing 
apoptosis and necrosis. H9c2 cells were kept in a serum 
free medium for 72 hours, while they were exposed to 
various GHRH agonists at 1 μmol/L concentrations. Cells 
cultured in a medium containing FBS served as negative 
control, and cardiac cells in a nutritionally deprived 
medium, without any treatment, were the positive control. 
When compared to the positive control, all the tested 
GHRH-agonists significantly decreased the calcium 
influx in the H9c2 cells, 175.6% increase in the positive 
control vs. 146.3%, 119.1%, 147.9%, 141.3%, 105.1%, 
90.2%, and 137.9%, in the cells treated with JI-38, MR-
356, MR-361, MR-367, MR-403, MR-409, and MR-502, 
respectively (Figure 2B). However, two of these analogs, 
MR-403 and MR-409, which almost completely inhibited 
calcium influx, showed no significant difference when 
compared to the negative control.
Effect of GHRH agonists on the expression 
of genes responsible for signal transduction 
activation and inhibition in H9c2 cell line
We investigated the actions of GHRH and its 
signaling in H9c2 cell line to determine mechanisms 
responsible for the survival observed in the treated cells. 
The Rat Signal Transduction Pathway Finder PCR array 
used in our study provided a simple and sensitive tool 
for profiling the expression of 84 key genes responsible 
for signal transduction pathway activation or inhibition. 
We identified important functional molecules affected by 
treatment with the GHRH agonists and selected genes 
potentially related to cell death, senescence and cardiac 
remodeling. After treatment with MR-409 more than 20 
genes in the H9c2 cells exhibited significant transcriptional 
change in mRNA expression relative to control, and 
also relative to cells cultured in a nutritionally deprived 
environment without exposure to GHRH agonists (Table 1).
Importantly, expression of axin-2, cyclin dependent 
kinase inhibitor 1A (Cdkn1A), fos-like antigen 1 
(Fosl1) and inhibitor of DNA binding 1 (Id1) genes 
were markedly downregulated (−8.11, −4.99, −7.57 
and −6.15 fold, respectively) by MR-409 (Table 1). 
Similarly, transcription of genes encoding pro-apoptotic 
proteins, including Bcl-2 binding component 3 and 
Bcl-2 related protein A1d, was decreased (−3.53 and −14.2 
fold, respectively) compared to the control group. We 
demonstrated a significant increase (4.53 and 5.98 
fold, respectively) in the transcription of genes of bone 
morphometric proteins 2 and 4 (BMP2 and BMP4), 
respectively, in response to MR-409 treatment (Table 1). 
In addition, MR-409 decreased transcription of Serpine-1 
gene, which encodes the plasminogen activator inhibitor-1 
(PAI-1), a protein which is involved in extracellular matrix 
(ECM) synthesis and remodeling.
Impact of GHRH analogs on myocardium 
infarct burden, scar thickness and vessel 
formation
To explore the mechanism by which agonists of 
GHRH improve cardiac performance following acute 
MI [4, 28], we selected three GHRH agonists (JI-38, 
MR-356 and MR-409) and examined their relationship to 
proliferative capacity of myocytes, vascular density and 
infarct size.
Infarct size was determined by morphometric 
measurements [29]. Our previous results [28] showed 
Figure 2: Effect of GHRH agonists at 100 nmol/L concentration on A. survival, and at 1 μmol/L concentration on 
B. Ca++-influx in H9c2 cardiomyoblast cells cultured in a nutrition-deprived medium. All values represent means ± SEM. 
*p < 0.05, †p < 0.01, ‡p < 0.001, vs. placebo positive control and §p < 0.001 vs. vehicle control.
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that size of the MI was substantially reduced by 
GHRH-agonists, JI-38 (42 ± 1%), MR-356 (37 ± 2.5%) 
and MR-409 (42 ± 2.4%) vs. placebo (49 ± 2%, p < 0.05 
for all) confirming the agonists’ cardioprotective effect. In 
addition, most of the hearts treated with GHRH analogs 
showed presence of viable myocardium in the scar area 
in contrast to the untreated hearts; in general, the average 
infarct wall thickness in the mid ventricle tended to be 
thicker than in the placebo group (Figure 3A and 3B).
Next combined isolectin and smooth muscle 
22 alpha (SM22A) staining was used to identify arterioles 
(Figure 4), since they are of obvious importance for 
myocardium perfusion and oxygen supply. All animals 
treated with GHRH analogs showed higher vascular 
density (p < 0.05 vs. placebo). We also observed an 
inverse correlation between infarct size and vascular 
density (p = 0.0002, r = −0.7562).
Effect of GHRH agonists on the magnitude of 
cardiomyocyte turnover and on cell proliferation
Cardiomyocyte mitotic division and c-kit expression 
were assessed by immunofluorescence. Treatment with 
GHRH analogs increased the number of endogenous cardiac 
c-kit+ cells and the cellular mitotic division (mitotic marker 
pH3) in the myocardium (Figure 5A and 5B, respectively). 
Figure 3: Impact of GHRH agonists on myocardium infarct burden and scar thickness. A. Representative images of 
Masson-Trichrome staining showing reduced infarct size and presence of viable tissue in the scar area of the treated hearts. B. Bar graphs 
correspond to scar thickness. All values represent means ± SEM (n = 4–6).
Table 1: Relative expression of genes related to cardiac remodeling in H9c2 rat cardiomyoblast 
cells after treatment with GHRH agonist, MR-409
Gene Fold change
Axin-2 − 8.11
Bcl-2 binding component 3 − 3.53
Bcl-2 related protein A1d − 14.2
Bone morphogenetic protein 2 4.53
Bone morphogenetic protein 4 5.98
Cyclin dependent kinase inhibitor 1A − 4.99
Fos-like antigen 1 − 7.57
Inhibitor of DNA binding 1 − 6.15
Serpine 1 − 4.66
Modulated genes with at least 3-fold change relative to the untreated control after treatment of H9c2 cells with the GHRH 
agonist MR-409.
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Figure 4: Effect of therapy with GHRH agonists on vessel formation. A. Bar graphs represent the number of arterioles 
per mm2. All values represent means ± SEM (*p < 0.05 vs. placebo, n = 4–6). B. Confocal immunofluorescent image of smooth muscle 
22 alpha (SM22A, green), isolectin B4 (red) and nuclei (DAPI, blue) staining. Scale bar: 50 μm.
Figure 5: Effect of GHRH agonists on cardiomyocyte turnover and cell proliferation. Immunostaining analysis of c-kit 
expression A. and cardiomyocyte mitosis B. based on the nuclear expression of phospho-histone H3 (pH3). Bar graphs show expression 
of c-kit+ cells and pH3
+ cells per mm2 (*p < 0.05 vs. placebo, n = 5–6), respectively. Representative confocal immunofluorescent images 
illustrating expression of c-kit (red), CD45 (green) and nuclei (DAPI, blue) on the top panel (Scale bar: 20 μm) and co-localization of pH3 
(magenta) and myosin light chain (MLC, green) and nuclei (DAPI, blue) on the bottom panel (Scale bar: 10 μm).
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Furthermore, an inverse correlation was identified between 
MI size and c-kit expression (p = 0.0084, r = −0.5471) and 
cardiomyocyte mitotic division (p = 0.0096, r = −0.5390).
Effect of administration of GHRH on levels of 
inflammation-related cytokines post-MI
Next, we investigated the action of GHRH 
agonist on the levels of inflammatory cytokines after MI 
(Figure 6). One week after starting the treatment with 
MR-409, there was a significant reduction in plasma IL-2, 
IL-6, IL-10 and TNF-α in comparison to placebo group 
(p < 0.05, n = 3 for each group).
Effects of GHRH agonist therapy on the 
expression of genes related to ECM
Relative gene expression levels of tissue inhibitor of 
metalloproteinase 1 (TIMP-1) and 2 (TIMP-2), collagen 
types I and III, and insulin-like growth factor binding 
protein 5 (IGFBP5) were assessed by RT-PCR in the 
placebo and in the MR-409 groups (Figure 7; Table 2). 
Hearts treated with MR-409 showed markedly increased 
expression of genes related to ECM (  p < 0.05 vs. placebo), 
with the exception of IGFBP5 (  p = ns).
DISCUSSION
This work confirms and extends findings that 
GHRH agonists are cardioprotective following myocardial 
injury [4, 5, 28] . Consistent with our previous report, 
the reductions on MI size by GHRH agonists were 
accompanied by an increased number of resident cardiac 
c-kit+ cells, an increase in the number of cellular mitotic 
divisions in the myocardium, and also by increased 
vascular density in the myocardium.
In order to further investigate the mechanisms 
involved, we examined the levels of circulating 
inflammatory cytokines to elucidate the influence 
of GHRH treatment on LV remodeling. Normally, 
following MI, pro-inflammatory factors secreted by 
cardiac tissue, including cardiomyocytes and fibroblasts, 
may amplify cardiac injury and fibrosis [30]. Several 
factors are involved in the pathogenesis of maladaptive 
cardiac remodeling. Inflammatory reactions, including 
those mediated by cytokines, chemokines, and matrix 
metalloproteinases (MMPs) may play important roles in 
the progression of CHF. For instance, circulating levels of 
interleukin 6 (IL-6) are elevated after MI and are associated 
with increased morbidity and mortality [31]. Early 
inhibition of inflammatory cytokines in the treated group 
may thus preserve myocardial tissue, contribute to more 
effective tissue healing with reduced scar tissue formation, 
and thereby decrease mortality and morbidity. Importantly, 
our results demonstrate that administration of GHRH 
agonist, starting two hours after MI, reduces the levels 
of circulating inflammatory cytokines (IL2, IL-6 IL-10 
and TNF-α) at one-week following MI. These findings 
suggest that GHRH-R activation can abolish the feedback 
loop of inflammation in the myocardium after ischemia.
We next examined the impact of treatment with these 
GHRH analogs on mRNA levels of ECM related genes. Our 
data show a substantial upregulation of genes related to the 
fibrosis pathway. The main action of TIMPs is to inhibit 
MMPs, but several groups have reported that TIMPs also 
have cell growth promoting, anti-apoptotic, steroidogenic 
and antiangiogenic activities [30, 32, 33], which are in part 
independent of their inhibition of MMP. Importantly, both 
TIMP-1 and TIMP-2 may activate the growth of fibrobasts 
in vitro [32–34], in addition to their MMP suppression. Thus, 
TIMPs may favor cardiac fibrosis not just by inhibiting 
MMPs, but also by separate direct pro-fibrotic mechanisms.
As the use of animals in experimental research is 
discouraged, H9c2, a clonal myogenic cell line derived 
from embryonic rat heart, has served as a surrogate for 
cardiac and skeletal cells and has become an important 
tool for toxicology [35] and signal transduction studies 
Figure 6: Impact of GHRH agonists on circulating cytokines post-MI. One-week post-MI, treatment with MR-409 produced 
a significant reduction in plasma levels of IL-2, IL-6, IL-10 and TNF-α in comparison to the placebo group (*p < 0.05, n = 3 for each group).
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Figure 7: Effects of GHRH agonist therapy on the expression of genes involved in extracellular matrix (ECM). Hearts 
treated with MR-409 had markedly increased mRNA levels of TIMP-1, TIMP-2, and collagen I, and III (*p < 0.05 vs. placebo). There was no 
significant change in the expression of IGFB5. Results are displayed as average and standard error of the mean of triplicate samples (n = 3–4).
Table 2: TaqMan® probes used to examine the impact of treatment with GHRH analogs on mRNA 
levels of extracellular matrix (ECM) related genes
Gene TaqMan® probe
GAPDH Rn99999916_s1
TIMP-1 Rn00587558_m1
TIMP-2 Rn00573232_m1
Collagen I Rn01463848_m1
Collagen III Rn01437681_m1
IGFBP5 Rn00563116_m1
in the heart. Accordingly, our in vitro results show that 
treatment of H9c2 cells with GHRH agonists improved 
the cell viability in the presence of nutritionally deprived 
serum. The survival of the H9c2 cells with GHRH 
agonist treatment increased by an average of 22.02% 
when compared to the positive control. In addition, 
the starvation-induced increase in calcium influx 
was abolished by GHRH agonist treatment. Next, we 
investigated multiple signal transduction pathways 
involved on these effects.
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Interestingly, our array data show that axin-2 
(a classical target of the canonical Wnt pathway), a negative 
regulator of beta-catenin, was suppressed by MR-409, 
indicating modulation of the beta-catenin pathway. The 
exact role of beta-catenin in adult cardiac remodeling 
in vivo is still not understood; however, downregulation of 
beta-catenin is required for adaptive cardiac hypertrophy. 
mRNA levels of axin-2 were significantly increased 
in human fibrotic diseases and in murine experimental 
fibrosis [36]. Mastri et al showed that reduction of axin-2 
expression, following downregulation of secreted Frizzled-
related protein 2 (sFRP2) by mesenchymal stem cell 
therapy and sFRP2 antagonism by antibody blockage, 
counteracts the fibrogenic pathway and improves 
myocardial injury repair [37]. Accordingly, axin-2 appears 
to promote ECM accumulation and fibrosis through the 
Wnt-dependent pathway. Our present data thus suggest that 
beneficial effects of GHRH agonists on cardiac remodeling 
may involve suppression of Wnt signaling; however, 
further analysis is required to confirm this mechanism.
Noteworthy, MR-409 markedly suppressed the 
expression of Serpine 1. Overall, fibrosis in multiple 
tissues has been associated with increased expression of 
Serpine 1, also known as plasminogen activator inhibitor-1 
(PAI-1) [38]. Serpine 1 is an inhibitor of plasmin action 
and was shown to be a target of TGF-β1, which implicates 
cross-talk between the members of the pro-fibrotic 
systems [39]. In addition, elevated levels of PAI-1 are 
associated with increased occurrence of thrombosis; and 
the decrease in its mRNA level may also protect against 
further ischemic events.
Recently, senescent cells are emerging as an 
important target in stem cell–based therapies, particularly, 
in the elderly population [40]. During the remodeling 
phase, senescent cells play a role in limiting scar formation 
by dissolving the fibrous proteins placed during the 
proliferative phase [41]. MR-409 limited the expression 
of Cdkn1A, an age-related gene tightly controlled by the 
p53 gene, which can modulate cell-cycle, differentiation, 
apoptosis, and senescence [42]. Torella et al [43] reported 
that downregulation of this gene can delay organ aging 
and heart dysfunction. On the other hand, Li et al [44] 
demonstrated that an increase in Cdkl1A expression occurs 
with an increase in apoptotic cells in rats with spontaneous 
heart failure.
The present findings also identified another factor 
related to age, Fosl1, a negative regulator of beta-catenin 
that plays an important role in limiting cell proliferation 
and differentiation [45]. Fosl1 has been characterized 
as a contributor to the AP-1 protein dimer complexes 
that regulate extracellular matrix, proliferation, and cell 
survival. In the presence of oxidative stress, FOSL1 can 
impair cell cycle entry or contribute to apoptosis.
Our data also show an overexpression of BMP2 and 
BMP4 genes. Accordingly, Wu et al. has reported that 
human recombinant BMP4 promotes survival in a cardiac 
muscle cell line after H
2
O
2
 injury, and also protects adult 
mouse cardiomyocytes against hypoxia-reoxygenation 
injury [46]. Therefore, this may be another one of the key 
mechanisms for the protection of the myocardium by the 
agonists.
In conclusion, activation of GHRH receptor in the 
heart by GHRH agonists may reduce the inflammatory 
response after MI and consequently improve the healing 
and cardiac remodeling by regulating pathways involved 
in fibrosis, apoptosis and mobilization of progenitor 
cells. This leads to significant recovery of the damaged 
myocardium and restitution of cardiac function. The 
reduction of MI size and increase in the number of mitotic 
cardiomyocytes provide evidence that administration of 
GHRH agonists enhances myocyte renewal and stimulates 
cardiac growth after MI, providing an effective therapeutic 
strategy to rescue/repair the infarcted heart. All three 
structural classes of the new compounds: methylamide 
analogs (MR-406 and MR-409), ethylamide analogs 
(MR-420 and MR-421) and C-terminal agmatine analogs 
(MR-356) are endowed with important endocrine and 
cardioprotective activities, and therefore such agonists 
could be useful for therapy of cardiovascular diseases, 
targeting specifically fibrogenic pathways.
MATERIALS AND METHODS
Peptides and reagents
In a search for more potent GHRH agonists, we 
synthesized, purified, and tested, both in vitro and in vivo, 
a series of new human GHRH(1–29) analogs. GHRH-
agonists JI-38, MR-356, MR-361, MR-367, MR-403, 
MR-409, and MR-502 were synthesized by solid phase 
methods and purified by reversed-phase high-performance 
liquid chromatography as described previously [28]. The 
chemical structures listed in comparison with the older 
agonist, JI-38, are the following:
JI-38: [N-Dat1, Ala2, Phe6, Gln8, Orn12, Abu15, Orn21, 
Nle27, Asp28, Agm29]hGHRH(1–29)NH
2
MR-356: [N-Me-Tyr1-JI-38]
MR-361: [N-Me-Tyr1, D-Ala2-JI-38]
MR-367: [N-Me-Tyr1, D-Ala2, Asn8-JI-38]
MR-403: [N-Me-Tyr1, D-Ala2, Arg29-NHCH3-JI-38]
MR-409: [N-Me-Tyr1, D-Ala2, Asn8, Arg29-NHCH3-
JI-38]
MR-502: [D-Ala2, Phe(F)5
6, Ser28, Arg29, Gab30-NH
2
-
JI-38]
Noncoded amino acids and acyl groups are 
abbreviated as follows: Abu, alpha-aminobutyric acid; 
Agm, agmatine; Dat, des-amino-tyrosine; Phe(F)5, 
pentafluoro-phenylalanine; Gab,  gamma-amino-butanoyl; 
hGHRH, human GHRH; Nle, norleucine; Orn, ornithine; 
N-Me-Tyr, N-methyl-tyrosine. The stability and purity 
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of the compounds were checked by HPLC before the 
experiments. For in vitro studies, the peptides were 
dissolved in dimethyl-sulfoxide (DMSO) to final 
concentrations that did not exceed 0.1%. For in vivo 
studies, the peptides were dissolved in 0.1% DMSO in 
sterile aqueous 10% propylene glycol (vehicle).
Cell line
Rat cardiomyoblast cell line, H9c2, was obtained 
from American Type Culture Collection (ATCC, 
Manassas, VA) and maintained in culture using Dulbecco’s 
Modified Eagles’s Medium (Invitrogen, Grand Island, NY) 
supplemented with 10% fetal bovine serum (FBS) and 
antibiotics (100 U/ml penicillin, 100 mg/ml streptomycin). 
Cells were grown at 37°C in a humidified 95% air/5% 
CO
2
 atmosphere.
Cell survival assay (MTS assay)
Cells (104/well) were seeded onto 96-well plates 
in 100 μl of culture medium containing 10% FBS, 
cultured overnight, then starved for 72 hours in a medium 
without fetal bovine serum (FBS). Cells in starving 
medium were exposed to hGHRH(1–29)NH
2
, or one of 
the GHRH agonists JI-38, MR-356, MR-361, MR-367, 
MR-403, MR-409, or MR-502, at a concentration of 
100 nmol/L. Cell viability was evaluated by using a 3-(4, 
5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfonphenyl)-2H-tetrazolium (MTS) assay (CellTiter 
96 Aqueous 1 Solution Cell Proliferation Assay; 
Promega, Madison, WI) according to the manufacturer’s 
instructions. Absorbance was measured at 490 nm in a 
Victor 3 Multilabel Counter (Perkin-Elmer, Waltham, 
MD). All experiments were done in quadruplicate and 
were repeated 3 times. The inhibition of cell proliferation 
was expressed as the percentage of vehicle control (0.1% 
DMSO in the culture medium).
Fluorescent assay for calcium mobilization
Cells (104/well) were seeded onto 96-well plates 
with 100 μl of culture medium containing 10% FBS, 
cultured overnight, then starved for 72 hours in medium 
without FBS. Cells in starving medium were exposed to 
hGHRH, or one of the GHRH agonists JI-38, MR-356, 
MR-361, MR-367, MR-403, MR-409, or MR-502 at a 
concentration of 1 μmol/L. Calcium mobilization was 
evaluated by using (Fluo-Forte® Calcium Assay Kits, 
Enzo Life Sciences, Framingdale, NY) according to 
the manufacturer’s instructions. Fluorescence intensity 
was measured at excitation and emission wavelengths 
of 485 nm and 535 nm, respectively, with a Victor 
3 Multilabel Counter. Intracellular calcium mobilization 
was expressed as a percentage of vehicle control (0.1% 
DMSO in the culture medium).
Animal model
Recently, our group reported the endocrine and 
cardioprotective activities of several GHRH agonists 
[33]. Based on our findings, we selected tissues from three 
groups with enhanced activities in the heart for further 
analysis. Plasma (obtained at 1 week post-MI) and basal 
portions of hearts, free of fibrotic tissue, were flash-frozen 
in liquid nitrogen for total RNA isolation. Remaining 
tissue was fixed in 10% formalin (EMD Millipore, 
Billerica, MA) for histology. All animal procedures were 
carried out in accordance with the Guide for the Care and 
Use of Laboratory Animals (National Institutes of Health, 
revised 2011) and approved by the University of Miami 
Institutional Animal Care and Use Committee.
Total RNA isolation and Reverse Transcription-
Polymerase Chain Reaction (RT-PCR)
The expression of full-length pituitary GHRH 
receptor (pGHRH-R) and GHRH was detected by RT-PCR. 
Total RNA was isolated using NucleoSpin kit (Macherey-
Nagel Inc., Bethlehem, PA). The yield and quality of total 
RNA was determined spectrophotometrically using 260 nm 
and 260/280 nm ratio, respectively. Genomic DNA was 
eliminated using Turbo DNA-free kit (Life Technologies, 
Carlsbad, CA). One and a half μg of RNA was reverse 
transcribed into cDNA with the RevertAid H minus RT Kit 
(Thermo Fisher Scientific, Waltham, MA) using a VeritiTM 
96-well thermal cycler (Applied Biosystems, Foster City, 
CA). We evaluated the mRNA expression of GHRH-R, 
GHRH, and β-actin by using the Go Taq Flexi DNA 
polymerase kit (Promega, Madison, WI) with primers and 
method described previously [4, 47]. Normal rat pituitary 
was used as positive control. A sample that contained 
DNAse digested RNA and no enzyme during reverse 
transcription was used as negative control for RT-PCR.
In addition, total RNA from the remote area of left 
ventricle was isolated by the TriZol method (Invitrogen, 
Carlsbad, CA) as previously described [16]. We determined 
the mRNA expression of genes involved in ECM. Samples 
tested were obtained from 3–5 independent experiments.
Histology
Slides were prepared with H&E and Masson’s 
trichrome stain to assess cardiac structure and the presence 
and extent of fibrosis and myocardial scar, respectively. 
The infarct size was determined by morphometric 
measurements calculated as previously described with 
minor modifications [35]. Briefly, MI size was calculated 
by dividing the perimeter of the infarcted wall by the total 
LV perimeter wall using Adobe Photoshop-CS3 (Adobe 
Systems Inc., San Jose, CA, USA). An average of four 
sections of each heart was used to measure the infarct 
size. To evaluate the scar thickness, we measured the scar 
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at midventricular level, averaging 3 measurements along 
the infarct wall. All measurements were performed blindly 
(n = 4–6 for each group) to avoid sampling bias.
Immunofluorescence staining
Heart sections were deparaffinized with xylene 
and rehydrated in alcohol series and water as previously 
described [4]. Omission of the primary antibodies on 
parallel sections was used as negative control. Nuclei 
were labeled with 4′,6-diamidino-2-phenylindole 
(DAPI, Invitrogen, Carlsbad, CA). The total numbers 
of positively-stained cells at midventricular level were 
quantified per slide to calculate the number of cells per 
square mm (mm2) on each sample. All images were 
obtained with a fluorescent microscope (Olympus IX81, 
Olympus America Inc., Center Valley, PA) or a LSM710 
Zeiss confocal laser-scanning module (Carl Zeiss 
MicroImaging, Germany).
Dual fluorescence immunostaining for isolectin 
B4 conjugated to Alexa 568 (Invitrogen, Carlsbad, CA) 
and α-SM22A (rabbit polyclonal, Abcam, Cambridge, 
MA) followed by donkey anti-rabbit FITC (Jackson 
ImmunoResearch Laboratories, West Grove, PA) was 
carried out to quantify arteriole density. The whole heart 
section at midventricular level was used for counting 
vessel profiles and the vascular density was expressed as 
arterioles per square mm (mm2).
Detection of inflammatory cytokines using 
ELISA
The panel of inflammatory cytokines was measured 
in plasma samples collected from control and MR-409 
treated groups at 1 week after treatment (n = 3 for each 
group) using the rat cytokine Multi-analyte Elisarray kit 
(Qiagen Inc., Valencia, CA). The arrays were performed 
according to manufacturer’s instructions. Absorbance 
was measured at 450 nm within 30 minutes of stopping 
the reaction. We measured production of the following 
cytokines: IL1α, IL1β, IL2, IL4, IL6, IL10, IL12, 
IL13, IFN-γ, TNF-α, granulocyte-macrophage colony 
stimulating factor (GM-CSF) and RANTES.
Statistical analysis
For statistical evaluation, SigmaStat 3.0 software 
(Stat Software, San Jose, CA) or GraphPad Prism software 
(San Diego, CA, USA) version 5.0 for Windows was used. 
Results are expressed as mean ± SEM. One-way analysis 
of variance (ANOVA) followed by Bonferroni t-test or a 
two tailed Student’s t-test were used where appropriate, 
and significance was accepted at p < 0.05. Correlations 
between MI size and vascular density, c-kit expression 
and cardiomyocyte mitotic division were tested by linear 
regression analysis.
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